JP2020502058A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502058A5
JP2020502058A5 JP2019526217A JP2019526217A JP2020502058A5 JP 2020502058 A5 JP2020502058 A5 JP 2020502058A5 JP 2019526217 A JP2019526217 A JP 2019526217A JP 2019526217 A JP2019526217 A JP 2019526217A JP 2020502058 A5 JP2020502058 A5 JP 2020502058A5
Authority
JP
Japan
Prior art keywords
indazole
carboxamide
fluorophenyl
chlorophenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019526217A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502058A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/061223 external-priority patent/WO2018093696A1/en
Publication of JP2020502058A publication Critical patent/JP2020502058A/ja
Publication of JP2020502058A5 publication Critical patent/JP2020502058A5/ja
Ceased legal-status Critical Current

Links

JP2019526217A 2016-11-18 2017-11-13 ジアシルグリセリドo−アシルトランスフェラーゼ2の阻害薬として有用なインダゾール誘導体 Ceased JP2020502058A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662424066P 2016-11-18 2016-11-18
US62/424,066 2016-11-18
PCT/US2017/061223 WO2018093696A1 (en) 2016-11-18 2017-11-13 Indazole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2

Publications (2)

Publication Number Publication Date
JP2020502058A JP2020502058A (ja) 2020-01-23
JP2020502058A5 true JP2020502058A5 (enExample) 2020-10-22

Family

ID=62145755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019526217A Ceased JP2020502058A (ja) 2016-11-18 2017-11-13 ジアシルグリセリドo−アシルトランスフェラーゼ2の阻害薬として有用なインダゾール誘導体

Country Status (12)

Country Link
US (1) US11104690B2 (enExample)
EP (1) EP3541374A4 (enExample)
JP (1) JP2020502058A (enExample)
KR (1) KR20190078646A (enExample)
CN (1) CN110121341A (enExample)
AU (1) AU2017360939B2 (enExample)
BR (1) BR112019010164A2 (enExample)
CA (1) CA3043203A1 (enExample)
MA (1) MA46856A (enExample)
MX (1) MX2019005786A (enExample)
RU (1) RU2019117556A (enExample)
WO (1) WO2018093696A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
US11787810B2 (en) 2020-05-18 2023-10-17 Merck Sharp & Dohme Llc Diacylglyceride O-acyltransferase 2 inhibitors
US12410159B2 (en) * 2020-10-08 2025-09-09 Merck Sharp & Dohme Llc Preparation of oxindole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors
KR20230084258A (ko) 2020-10-08 2023-06-12 머크 샤프 앤드 돔 엘엘씨 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의 벤즈이미다졸론 유도체의 제조
KR20230124989A (ko) * 2020-12-22 2023-08-28 머크 샤프 앤드 돔 엘엘씨 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의테트라히드로인다졸 유도체의 제조
KR20240165402A (ko) 2022-03-23 2024-11-22 아이디어야 바이오사이언시스 인코포레이티드 Parg의 억제제로서의 피페라진 치환된 인다졸 화합물
CN120500483A (zh) 2022-12-02 2025-08-15 默沙东有限责任公司 作为新型二酰基甘油o-酰基转移酶2抑制剂的稠合唑衍生物的制备

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334213A (en) * 1996-09-04 2000-08-25 Pfizer Indazole derivatives as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) for treating asthma, arthritis, bronchitis, CNS disorders
ATE253073T1 (de) 1997-03-07 2003-11-15 Metabasis Therapeutics Inc Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase
WO1998039342A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
EP1112275B9 (en) 1998-09-09 2004-03-10 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
WO2002008188A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
AU2002240235B2 (en) 2001-01-30 2006-07-06 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
WO2003045385A1 (en) * 2001-11-27 2003-06-05 F. Hoffmann-La Roche Ag Benzothiazole derivatives
US20090286791A1 (en) 2001-11-27 2009-11-19 Takeda Pharmaceutical Company Limited Amide Compounds
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
CA2495915A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
DK1537078T3 (da) 2002-08-29 2010-08-02 Merck Sharp & Dohme Indoler med anti-diabetisk aktivitet
US7319170B2 (en) 2003-01-17 2008-01-15 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzensulfonmide derivatives
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
ATE531706T1 (de) 2005-04-30 2011-11-15 Boehringer Ingelheim Int Neue piperidin-substituierte indole und ihre verwendung als ccr-3-modulatoren
WO2007084435A2 (en) 2006-01-13 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
WO2008088692A2 (en) 2007-01-12 2008-07-24 Merck & Co., Inc. Spirochromanon derivatives
CA2691010A1 (en) 2007-06-28 2008-12-31 Merck Frosst Canada Ltd. Substituted fused pyrimidines as antagonists of gpr105 activity
CN101743616B (zh) 2007-06-28 2012-02-22 株式会社半导体能源研究所 半导体装置的制造方法
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
WO2009042053A2 (en) 2007-09-21 2009-04-02 Merck & Co., Inc. Neuromedin u receptor agonists and uses thereof
JP2011502148A (ja) 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛の治療用としてのp2x3受容体アンタゴニスト
US8461185B2 (en) 2007-10-31 2013-06-11 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
CA2741666C (en) 2008-10-31 2017-04-11 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
EP2210891A1 (en) 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
AU2010226829A1 (en) 2009-03-18 2011-09-15 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
US9238647B2 (en) 2009-03-23 2016-01-19 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
EP2410858B1 (en) 2009-03-23 2016-09-07 Merck Sharp & Dohme Corp. P2x3 receptor antagonists for treatment of pain
AU2010229144B2 (en) * 2009-03-23 2012-07-12 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
WO2010118009A1 (en) 2009-04-06 2010-10-14 Ptc Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
WO2014026329A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
EP3188731B1 (en) 2014-09-05 2019-04-03 Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
EP3188732B1 (en) 2014-09-05 2019-07-24 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
EP3188730B1 (en) * 2014-09-05 2019-05-01 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
EP3298001B1 (en) 2015-05-20 2020-05-13 Eli Lilly and Company Dgat2 inhibitors

Similar Documents

Publication Publication Date Title
JP2020502058A5 (enExample)
RU2019117556A (ru) Индазольные производные, пригодные в качестве ингибиторов диацилглицерид o-ацилтрансферазы 2
RU2017124425A (ru) Производные 2,4-диоксо-хиназолин-6-сульфонамида в качестве ингибиторов parg
RU2485114C2 (ru) Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов
RU2452738C2 (ru) Соединения, модулирующие активность c-fms и/или c-kit, и их применения
JP2020506946A5 (enExample)
RU2017125520A (ru) Соединения, ингибирующие parg
JP5687903B2 (ja) キヌレニン産生抑制剤
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
JP2010533158A5 (enExample)
JP2017538750A5 (enExample)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
JP2016523911A5 (enExample)
JP2018535999A5 (enExample)
RU2021127810A (ru) Замещенные гетероарилом пиридины и способы применения
JP2019518036A5 (enExample)
RU2019132212A (ru) Селективные ингибиторы hdac6
HRP20191327T1 (hr) 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primjenju u liječenju kardiovaskularnih poremećaja
JP2019509319A5 (enExample)
JP2018530591A5 (enExample)
RU2016102137A (ru) Первичные карбоксамиды в качестве ингибиторов bik
JP2017537948A5 (enExample)
CN112370452A (zh) 作为激酶抑制剂的杂环酰胺
JP2017500364A5 (enExample)
JP2010508338A5 (enExample)